Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
about
Celiac disease: prevalence, diagnosis, pathogenesis and treatmentNon-dietary forms of treatment for adult celiac diseaseBetween celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivityIn vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tractIntestinal microbiota in functional bowel disorders: a Rome foundation reportThe potential utility of tight junction regulation in celiac disease: focus on larazotide acetateTherapeutic approaches for celiac diseaseAnimal models to study gluten sensitivityHost responses to intestinal microbial antigens in gluten-sensitive miceCeliac disease.Identification of gliadin-binding peptides by phage display.Novel therapies for coeliac diseaseGluten-free diet in nonceliac disease.Review article: coeliac disease, new approaches to therapy.Can dietary fibre help provide safer food products for sufferers of gluten intolerance? A well-established biophysical probe may help towards providing an answer.BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity.Prevention measures and exploratory pharmacological treatments of celiac disease.Modulatory Effect of Gliadin Peptide 10-mer on Epithelial Intestinal CACO-2 Cell Inflammatory ResponseCeliac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms.Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin.Polymeric drugs: Advances in the development of pharmacologically active polymers.Important lessons derived from animal models of celiac disease.Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice.Increased bacterial translocation in gluten-sensitive mice is independent of small intestinal paracellular permeability defectInterest in medical therapy for celiac disease.Investigational therapies for celiac disease.Enzymatic strategies to detoxify gluten: implications for celiac disease.Discovery of gluten as the injurious component in celiac disease.Pharmacotherapy and management strategies for coeliac disease.New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment.Experiences with animal models of dermatitis herpetiformis: a review.Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.In vitro models for gluten toxicity: relevance for celiac disease pathogenesis and development of novel treatment options.Targeting bacterial toxins.The interaction of dietary fibres with disulphide bonds (S-S) and a potential strategy to reduce the toxicity of the gluten proteins in coeliac disease.Future treatment strategies for celiac disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes.Recent advances in the development of new treatments for celiac disease.Latest in vitro and in vivo models of celiac disease.
P2860
Q22305490-91F7BB6B-9CBF-4B4A-9D84-EEB612F7E6F4Q24602271-064676E7-4F14-410A-8BAF-0B6EF9214049Q24623796-43FB73C3-15D9-48D6-A771-EDBB112A60A4Q24627253-0268978A-A647-40F9-AC8E-BF7C5FCF27ADQ24631357-96D10F76-BDD4-414B-B4BC-EA12204BFDC7Q26771888-AD3B5E9C-7531-48DE-B75D-5001FE26070BQ26825413-BE35A227-054C-4447-921B-55ED96545766Q26859130-2E8E0314-DE70-4C5D-A495-00F623F0544BQ33489534-516E524B-38C9-41BD-ACDD-EC811E909F5CQ33696823-13C93E09-5E79-448B-B391-AAA5520B7815Q33823074-B514BDA9-764F-4FC9-9F24-A3A6A2271EB3Q34170574-0A7E40C3-FADB-4D74-AE3C-FDE137768A3AQ34185602-501CA6F2-D26C-4F23-A61E-97E6B609F05DQ34253519-25D17AFC-A2F3-4F06-AB1F-11D89C0DA106Q34272450-DE796923-6B80-48A8-B85F-9356D7ADE45AQ34443779-EB6F7E0A-E387-4741-A512-8958068D7190Q34623902-07030B21-E17D-492B-9893-DCE37907833FQ34792825-E2CD8AAA-63BE-4E4C-9E4B-8A17E87250A1Q34809320-68984EFF-76E4-41A9-9C07-BC8ED51D97CDQ35686518-A633A183-0CB1-4BAE-BDE5-DB4D4A063FB0Q36307604-015B0EC8-1893-49FD-8C14-87941944ADE1Q36344842-C598A0F1-0A41-4CFF-B666-8B987A7A0564Q36383508-6B343835-652E-4079-97AE-3AD043A75179Q36426072-39D2DC9F-2CD1-47A6-A75E-D85D078F62EEQ37130612-C6C91EE0-ED25-4D60-A061-4CA588D7DEC1Q37638684-F2DCED8F-FF23-44BB-A037-361DD58B30BAQ37806959-040E582E-8CC7-4E83-A731-7681344ED083Q37859177-6D6C3777-4C20-473C-9F84-2CB497E06D4CQ37896092-155E24C6-349D-4431-85E7-1AFA2B7EB150Q37905046-772604C6-CB6A-443C-A203-1CDACD5D9DDDQ37934991-9AA2FBD5-6F85-4D38-BBBD-48E1E9B114B4Q37965669-E8DE2185-F6F5-4ACB-A203-A854117FDC50Q37979161-21BBFD82-377A-46E5-AB6E-8B15843855D8Q37996325-CF4407DA-E82F-48EF-B98D-76FF843F82CBQ38012150-2D9EDF86-2A8B-49C3-9798-57F989837754Q38012460-D2A15B10-DE7F-42F2-82E9-5A8BDD8504B6Q38016781-C16441F5-B1DA-4FD5-9F1D-ACFD4DB432F6Q38021639-6CBA4FBB-5CAB-40FF-A8C4-566BAC6BB535Q38038684-CB61F51D-43C1-4CD8-A214-4A1D37022B0DQ38072065-DE5A5344-7179-499E-883B-B38BAFEA44F2
P2860
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@en
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@nl
type
label
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@en
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@nl
prefLabel
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@en
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@nl
P2093
P1433
P1476
Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium.
@en
P2093
Anne Vézina
Chella S David
Elena F Verdu
Jean-Christophe Leroux
Maud Pinier
Mohamad Nasser-Eddine
Nathalie Rivard
P304
P356
10.1053/J.GASTRO.2008.09.016
P407
P577
2008-09-20T00:00:00Z